Aspireo Reports Somatoprim Phase I b Interim Data
Preliminary Data Analysis Supports Excellent Safety and Side Effect Profile of Somatoprim
Tel Aviv, Israel, January 7, 2013 / B3C newswire / - Aspireo
Pharmaceuticals Limited, (“Aspireo”) an Israeli
biopharmaceutical company, focused on the development of
Somatoprim, a novel somatostatin analog (SSA), today announced
results of an interim analysis of a phase I b study. This single
centre study is investigating the safety, side effect profile, as
well as pharmacokinetic and pharmacodynamic profile of multiple
ascending doses of Somatoprim in healthy male volunteers, when
administered alone and in combination with octreotide.
The preliminary data confirms the excellent safety profile of
Somatoprim, with the maximum tolerated dose not reached. No serious
adverse events were reported. The few reported adverse events were
generally mild to moderate and transient. Somatoprim also
demonstrated a dose-dependent lowering effect on growth hormone
(hGH), as shown by an analysis of the pharmacodynamic effect on
hGH, when stimulated by growth hormone releasing hormone. The
interim analysis also supports the beneficial side effect profile
of Somatoprim when compared to octreotide.
The company expects final data to be available in Q2 2013
About Somatoprim
Somatoprim (DG3173) is a novel and proprietary somatostatin analog
(SSA) that is based on a novel amino acid composition. Somatoprim
has demonstrated a unique receptor binding and pharmacological
profile which is significantly differentiated from SSAs that are
currently marketed or in clinical development. In particular,
Somatoprim has shown an improved side effect profile with reduced
adverse effects on the gastrointestinal tract and glucose
metabolism. Furthermore, assessment of growth hormone secretion in
cultured human somatotroph adenoma tissue treated with Somatoprim
indicates that it has the potential to increase the response rate
of acromegalic patients to SSA therapy. Somatoprim is currently in
phase I/II of clinical development. Somatostatin analogs have been
approved for the treatment of acromegaly, carcinoid tumours, and
Cushing’s disease but have also demonstrated significant
potential in diabetic retinopathy. Somatostatin analogs are
generating more than USD 1.5 billion in annual sales in a
continually growing market.
About Aspireo
Aspireo Pharmaceuticals Ltd is a biopharmaceutical company focused
on the development of a novel somatostatin analog (SSA) for the
treatment of diseases resulting from hormone-active tumors, such as
acromegaly, neuroendocrine and gastroenteropancreatic tumors,
Cushing’s Disease and diabetic retinopathy. Aspireo’s
sole development compound is Somatoprim (DG3173), a novel and
proprietary somatostatin analog that is based on a novel amino acid
composition and a unique backbone cyclization technology used for
stabilization of the peptide. Aspireo is an Israeli company
established in 2010 by TVM Capital as a Project Focused Company
(PFC). In September 2012 Aspireo and Evotec AG, Hamburg, Germany,
entered into a strategic advisory agreement whereby Evotec will
support Aspireo in the partnering of Somatoprim. For additional
information please go to www.aspireopharma.com
For further information please contact
Carsten Dehning
Chief Executive Officer
Aspireo Pharmaceuticals Limited
+49 (170) 6308687
dehning@aspireo.com
Posted: January 2013
